The Novavax technology platform produces two different types of immunogenic particles that form the basis of our vaccines: virus-like particles (or VLPs) and recombinant protein micelles.
Novavax’ clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 500 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax has been named a Washington Post Top Workplace for three years running.
Business Development Queriesbusdev@novavax.com